Olopatadine is a histamine-1 receptor inhibitor indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 years of age and older. MedsAcross supplies Olopatadine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Olopatadine hydrochloride nasal spray is indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 years of age and older. Olopatadine hydrochloride nasal spray is an H 1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 years of age and older.
Source: US FDA prescribing information
Olopatadine is a histamine H 1 receptor antagonist. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
Source: US FDA prescribing information
For nasal use only. Recommended dosages: Adults and Adolescents ≥12 Years: Two sprays per nostril (665 mcg per spray) twice daily. Pediatric Patients 6 to 11 Years: One spray per nostril (665 mcg per spray) twice daily. Priming Information: Prime olopatadine hydrochloride nasal spray before initial use and when olopatadine hydrochloride nasal spray has not been used for more than 7 days.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Epistaxis, Nasal Ulceration, and Nasal Septal Perforation: Monitor patients periodically for signs of adverse effects on the nasal mucosa. Discontinue if ulcerations or perforations occur. Avoid use in patients with nasal disease other than allergic rhinitis. Avoid engaging in hazardous occupations requiring complete mental alertness and coordination, such as driving or operating machinery when taking olopatadine hydrochloride nasal spray. Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal spray.
Source: US FDA prescribing information
The most clinically significant adverse reactions described in other sections of labeling include: Epistaxis, Nasal Ulceration, and Nasal Septal Perforation Somnolence and Impaired Mental Alertness The most common (> 1%) adverse reactions, included bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal drip, cough, and urinary tract infection in patients 12 years of age and older and epistaxis, headache, upper respiratory tract infection, bitter taste, pyrexia, and rash in patients 6 to 11 years of age.
Source: US FDA prescribing information
Formal drug-drug interaction studies were not conducted for olopatadine hydrochloride nasal spray. Drug interactions with inhibitors of liver enzymes are not anticipated because olopatadine is eliminated predominantly by renal excretion. Drug interactions involving P450 inhibition and plasma protein binding are also not expected.
Source: US FDA prescribing information
Storage Store olopatadine hydrochloride nasal spray at room temperature between 4°C to 25°C (39°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Olopatadine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Olopatadine 665 mcg nasal sprayNasalGeneric name | — | US FDA | Available on request |
| Olopatadine 1 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Olopatadine 2 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Olopatadine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Olopatadine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Olopatadine on 18 December 1996, according to Drugs@FDA.
Yes. Olopatadine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Olopatadine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Olopatadine is classified under ATC code R01AC08 (Olopatadine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.